Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 19/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 13/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 0.74 |
| ▸ | IL1B | P01584 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thalidomide SCHEMBL410642 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL15197560 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL41641 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL571278 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL455269 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL411178 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL411175 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL23420695 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL22772286 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL19586750 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 105261 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144783-A1 | COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL NEUROPATHY, CONTAINING ISOQUINOLINE DERIVATIVE AS ACTIVE INGREDIENT | ALTMEDICAL CO., LTD. (KR) | 2026-05-28 | — | — | US | claimed |
| EP-4748376-A2 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS | Janssen Biotech, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107492-A1 | REGULATION OF DELTA-2 TUBULIN FOR TREATING CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-1995004525-A2 | USE OF TUMOR NECROSIS FACTOR INHIBITORS TOGETHER WITH ANTIVIRAL AGENTS AND THERAPEUTIC COMPOSITIONS THEREOF AGAINST HIV INFECTION | ANDRULIS PHARMACEUTICALS CORPORATION (US) | 1995-02-16 | — | — | WO | claimed |
| WO-1995004533-A2 | TREATMENT OF RHEUMATOID ARTHRITIS WITH THALIDOMIDE ALONE OR IN COMBINATION WITH OTHER ANTI-INFLAMMATORY AGENTS | ANDRULIS PHARMACEUTICALS CORPORATION (US) | 1995-02-16 | — | — | WO | claimed |
| WO-1995003807-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | THE UNIVERSITY OF SYDNEY (AU) | 1995-02-09 | — | — | WO | claimed |
| US-5385901-A | Treating patients with 3-phthalimido-2,6-dioxopiperidine for toxic symptoms of septic shock, cachexia and HIV infection by inhibiting excessive production of tumor necrosis factor alpha | THE ROCKEFELLER UNIVERSITY (US) | 1995-01-31 | — | — | US | claimed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | claimed |
| WO-1994026241-A1 | USE OF HYDROXYNAPHTHALENES IN COLOURING AGENTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1994-11-24 | — | — | WO | claimed |
| WO-1994020085-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-09-15 | — | — | WO | claimed |
| WO-1992014455-A1 | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES | THE ROCKEFELLER UNIVERSITY (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0340591-A2 | Light-induced dark-hardening adhesives | Henkel Kommanditgesellschaft auf Aktien (DE) | 1989-11-08 | — | — | EP | claimed |
| EP-0140847-A2 | A computer printout and document holding device, formed by composable elements | CARTOPLAST BERTESI S.p.A. (IT) | 1985-05-08 | — | — | EP | claimed |